Function of Toll like receptor signaling pathway in the carcinogenesis process related to high risk HPV infection of cervical

Abstract

XU Xiao-Xian, LOU Han-Mei. Function of Toll like receptor signaling pathway in the carcinogenesis process related to high risk HPV infection of cervical[J]. Journal of International Oncology, 2014, 41(11): 840-843.

References

［1］ Kumar H， Kawai T， Akira S. Tolllike receptors and innate immunity［J］. Biochem Biophys Res Commun，2009，388(4): 621625. ［2］ Huang B， Zhao J， Li H， et al. Tolllike receptors on tumor cells facilitate evasion of immune surveillance［J］. Cancer Res， 2005， 65（12）:50095014. ［3］ CherfilsVicini J， Platonova S， Gillard M， et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance［J］. J Clin Invest， 2010， 120(4):12851297. ［4］ Lee JW， Choi JJ， Seo ES， et al. Increased tolllike receptor 9 expression in cervical neoplasia［J］. Mol Carcinog， 2007， 46（11）:941947. ［5］ Kim WY， Lee JW， Choi JJ， et al. Increased expression of Tolllike receptor 5 during progression of cervical neoplasia［J］. Int J Gynecol Cancer， 2008， 18（2）:300305. ［6］ Huang B， Zhao J， Unkeless JC， et al. TLR signaling by tumor and immune cells: a doubleedged sword［J］. Oncogene， 2008， 27(2):218224. ［7］ Bucala R. Macrophage migration inhibitory factor: a probable link between inflammation and cancer［J］. Immunity， 2007， 26（3）:281285. ［8］ Phan RT, DallaFavera R. The BCL6 protooncogene suppresses p53 expression in germinalcentre B cells［J］. Nature, 2004,432(7017): 635639. ［9］ Schmausser B, Andrulis M, Endrich S, et al. Tolllike receptors TLR4, TLR5 andTLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori［J］. Int J Med Microbiol, 2005, 295(2):179185. ［10］ Fukata M, Chen A, Vamadevan AS, et al. Tolllike receptor4 promotes the development of colitisassociated colorectal tumors［J］. Gastroenterology, 2007, 133(6):18691881. ［11］ Yu L, Wang L, Chen S. Dual character of Tolllike receptor signaling:protumorigenic effects and antitumor functions［J］. Biochim Biophys Acta, 2013, 1835(2):144154. ［12］ Daud II, Scott ME, Ma Y, et al. Association between tolllike receptor expression and human papillomavirus type 16 persistence［J］. Int J Cancer, 2011, 128(4):879886. ［13］ Yu L, Wang L, Li M, et al. Expression of tolllike receptor 4 is downregulated during progression of cervical neoplasia［J］. Cancer Immunol Immunother, 2010, 59(7):10211028. ［14］ Werner J, DeCarlo CA, Escott N, et al. Expression of integrins and Tolllike receptors in cervical cancer: Effect of infectious agents［J］. Innate Immunity, 2011, 18(1):5569. ［15］ Hasan UA, Bates E, Takeshita F, et al. TLR9 expression and function is abolished by the cervical cancer associated human papillomavirus type 16［J］. J Immunol, 2007, 178(5):31863197. ［16］ Huang CY, Chen JJW, Shen KY, et al. Recombinant lipidated HPV E7 induces a Th1biased immune response and protective immunity against cervical cancer in a mouse model［J］. PLoS One, 2012, 7(7):e40970. ［17］ Idoyaga J, Moreno J, Bonifaz L. Tumor cells prevent mouse dendritic cell maturation induced by TLR ligands［J］. Cancer Immunol Immunother, 2007, 56(8):12371250. ［18］ Yang R, Murillo FM, Delannoy MJ, et al. B lymphocyte activation by human papillomaviruslike particles directly induces Ig class switch recombination via TLR4MyD88［J］. J Immunol, 2005, 174(12): 79127919. ［19］ Xu Y, Hu Y, Shi B, et al. HBsAg inhibits TLR9mediated activation and IFNalpha production in plasmacytoid dendritic cells［J］. Mol Immunol, 2009, 46(13):26402646. ［20］ Xie Q, Shen HC, Jia NN, et al. Patients with chronic hepatitis B infection display deficiency of plasmacytoid dendritic cells with reduced expression of TLR9［J］. Microbes Infect, 2009, 11（4）：515523. ［21］ Shiina M, Rehermann B. Cell cultureproduced hepatitis C virus impairs lasmacytoid dendritic cell function［J］. Hepatology, 2008, 47(2):385395. ［22］ Hirsch I, Caux C, Hasan U, et al. Impaired Tolllike receptor 7 and 9 signaling :from chronic viral infections to cancer［J］. Trends Immunol, 2010, 31(10):391397. ［23］ Roszak A, Lianeri M, Sowińska A，et al. Involvement of Tolllike Receptor 9 polymorphism in cervical cancer development［J］. Mol Biol Rep, 2012, 39(8):84258430. ［24］ Pandey S, Mittal RD, Srivastava M, et al. Impact of Tolllike receptors ［TLR］2 (196 to 174 del) and TLR 4 (Asp299Gly,Thr399Ile) in cervical cancer susceptibility in North Indian women［J］. Gynecol Oncol, 2009, 114（3）:501505. ［25］ Bodelon C, Madeleine MM, Johnson LG, et al. Genetic variation in the TLR and NFκB pathways and cervical and vulvar cancer risk: A populationbased casecontrol study［J］. Int J Cancer, 2014, 134(2):437444.

[1]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[2]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying.Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2023, 50(8): 475-483.
[3]	Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376.
[4]	Ma Xueyan, Lu Lili, Sun Pengfei.Advances in the immune microenvironment in cervical cancer[J]. Journal of International Oncology, 2023, 50(1): 47-50.
[5]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou.Advances in immunotherapy for recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 517-520.
[6]	Shi Yingxia, Hu Lijun, Yu Jingping.Application of immune checkpoint inhibitors in the treatment of recurrent or metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 568-571.
[7]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng.Research progress of maintenance therapy for cervical cancer[J]. Journal of International Oncology, 2022, 49(7): 430-435.
[8]	Yuan Chenyang, Zhou Juying.Research progress on prognostic factors of cervical cancer[J]. Journal of International Oncology, 2022, 49(5): 307-313.
[9]	Wang Yue, Wu Qiong, Xu Yuan, Gong Wei, Xu Xiaoting.Screening and treatment progression of elderly cervical cancer[J]. Journal of International Oncology, 2022, 49(12): 754-758.
[10]	Ma Xiuzhen, Lu Yan, Zhao Bingbing, Qiu Hongcong, Xu Xun, Wei Min.Effects of total flavonoids from Baeckea frutescens on the migration, invasion and apoptosis of cervical cancer SiHa cells[J]. Journal of International Oncology, 2021, 48(4): 206-211.
[11]	Yu Mingyue, Chen Zhengzheng, Zhao Xuxu, Ren Pingping, Zhang Ying, Ge Li, Zhu Meiling, Zhao Weidong.Factors related to postoperative adjuvant therapy of locally advanced cervical cancer and building of a nomogram prediction model[J]. Journal of International Oncology, 2021, 48(1): 35-40.
[12]	Ding Xuchao, Cao Lili.Common active targeting nano drug delivery systems for cervical cancer[J]. Journal of International Oncology, 2021, 48(1): 61-64.
[13]	Shu Hang, Xu Zhonghua, Zhu Haochen, Yang Yahui, Lyu Yin.Research progress of radiosensitivity in cervical cancer[J]. Journal of International Oncology, 2020, 47(8): 496-500.
[14]	Song Mingze, Cheng Yiming, Li Gang, Wang Zhenming, Li Shirong.Value of P16/Ki-67 double staining detection in screening cervical cancer and precancerous lesions[J]. Journal of International Oncology, 2020, 47(11): 675-681.
[15]	Li Ang, Wei Fang.Current status and future challenges of HPV preventive vaccine of cervical cancer[J]. Journal of International Oncology, 2019, 46(5): 307-310.